Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

This publication has 10 references indexed in Scilit:

• Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients
  AIDS, 2007
• Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
  AIDS, 2007
• Treatment for Adult HIV Infection
  JAMA, 2006
• Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
  The Lancet, 2006
• Incidence and Risk Factors for Immune Reconstitution Inflammatory Syndrome in an Ethnically Diverse HIV Type 1-Infected Cohort
  Clinical Infectious Diseases, 2006
• Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
• TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates
  Antimicrobial Agents and Chemotherapy, 2005
• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
  AIDS, 2005
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• Allocation of Patients to Treatment in Clinical Trials
  Published by JSTOR ,1979